CEACAM5 and neoplasm: Even for stage IV CRC patients with a high tumor burden, the SDMBP model showed higher sensitivity than the assessment of the levels of CEA, CA199 and the combination of both (92.8% vs.69.6%, 40.6% and 69.6%) (Figures 5B, C).